<DOC>
	<DOCNO>NCT00140075</DOCNO>
	<brief_summary>The purpose study compare two combination drug , epirubicin give taxane ( ET ) epirubicin give cyclophosphamide ( cytoxan ) follow taxane see one combination well prevent delay time breast cancer recurrence death 3 year . The study also evaluate side effect treatment combination .</brief_summary>
	<brief_title>Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Breast Cancer Stage T13 , N1 , M0 Suitable candidate anthracyclinecontaining adjuvant chemotherapy Evidence residual tumor follow surgery , metastatic disease Received prior therapy breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>